L’Oréal Says GLP‑1 Weight‑Loss Drugs Dampening Beauty Sales

L’Oréal’s chief executive highlighted that the growing use of GLP‑1 based weight‑loss medications is affecting the company’s beauty and skin‑care divisions. He described the trend as "a very important phenomenon for us" and noted that it is reshaping consumer buying patterns.

The French cosmetics group said the drugs, which help users lose weight, are leading some shoppers to alter their grooming routines and reduce spending on traditional beauty products. L’Oréal is monitoring the shift closely as it evaluates its product strategy and marketing approaches across its global brands.

Why It Matters

The shift signals how medical weight‑loss treatments may affect the broader cosmetics market, a sector important to consumers and investors in the US and Europe.